New tenant for Clinical Innovation Zone
Causeway Therapeutics has signed up to be a new tenant in the Clinical Innovation Zone at the Queen Elizabeth University Hospital; its co-founders Dr Derek Gilchrist and Mr Neal Millar having previously worked in the laboratory of Professor Iain McInnes at the Institute of Infection, Immunity and Inflammation.
Dr Carol Clugston, Chief Operating Officer of the College said: “We're delighted that Causeway Therapeutics has chosen the University of Glasgow's Clinical Innovation Zone as the location for their exciting new company. The Clinical Innovation Zone comprises 22,000 sq ft of purpose-built space to facilitate biomedical innovation, by bringing industry, academia and the NHS together to create a thriving new life sciences cluster. This will provide economic benefit for Glasgow by supporting the growth of new companies, together with benefits for patients through the development of new diagnostics and treatments.” Read more.
First published: 7 August 2017